Earnings History Data for Oncternal Therapeutics, Inc. (ONCT) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Oncternal Therapeutics, Inc.
Oncternal Therapeutics Inc. is a clinical-stage oncology company. It is engaged in developing treatments for cancers with critical unmet medical need. The company's pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly known as GTx Inc., is based in San Diego, California.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 08-08-2024 | AH | ONCT | Oncternal Therapeutics, Inc. | 17.02 | -2.89 | -3.03 | 3.00 | Oncternal Therapeutics GAAP EPS of -$2.89 beats by $0.14, revenue of $0.8M beats by $0.64M [8/8/2024 4:13 PM] |
5.31 | -0.21 (-3.75%) |
5.50 | -0.02 (-0.36%) |
5.09 - 13.14 | 7,099 | 10,000 | 229 | ||
| 09-05-2024 | AH | ONCT | Oncternal Therapeutics, Inc. | 25.22 | -2.83 | -2.88 | 4.00 | Oncternal Therapeutics GAAP EPS of -$2.83 beats by $0.05, revenue of $0.57M beats by $0.44M [5/9/2024 5:01 PM] |
8.55 | -0.08 (-0.98%) |
9.05 | 0.42 (4.81%) |
5.57 - 13.14 | 2,459 | 0 | 542 | ||
| 07-03-2024 | AH | ONCT | Oncternal Therapeutics, Inc. | 28.12 | -3.11 | -3.09 | 4.00 | Oncternal Therapeutics GAAP EPS of -$3.11 misses by $0.03, revenue of $0.3M beats by $0.16M [3/7/2024 4:02 PM] |
9.52 | 0.27 (2.94%) |
9.23 | -0.02 (-0.22%) |
5.22 - 18.47 | 6,042 | 10,000 | 439 | ||
| 09-11-2023 | AH | ONCT | Oncternal Therapeutics, Inc. | 20.82 | -0.17 | -0.15 | -0.21 | Oncternal Therapeutics GAAP EPS of -$0.17 misses by $0.03, revenue of $0.18M beats by $0.05M [11/9/2023 4:16 PM] |
0.2950 | 0.0 (-1.63%) |
0.28 | -0.02 (-7.20%) |
0.26 - 1.33 | 141,019 | 140,000 | 22,367 | ||
| 10-08-2023 | AH | ONCT | Oncternal Therapeutics, Inc. | 19.37 | -0.15 | -0.17 | -0.23 | Oncternal Therapeutics GAAP EPS of -$0.15 beats by $0.02, revenue of $0.11M misses by $0.06M [8/10/2023 4:02 PM] |
0.3141 | -0.02 (-7.35%) |
0.35 | 0.01 (3.24%) |
0.26 - 1.40 | 242,590 | 260,000 | 13,483 | ||
| 09-03-2023 | AH | 4:00 PM ET (Mar 9) |
ONCT | Oncternal Therapeutics, Inc. | 54.59 | -0.20 | -0.22 | -0.16 | Oncternal Therapeutics GAAP EPS of -$0.20 beats by $0.01, revenue of $0.17M misses by $0.11M [3/9/2023 4:03 PM] |
0.75 | -0.14 (-15.36%) |
0.85 | -0.04 (-4.07%) |
0.69 - 1.87 | 768,123 | 200,000 | 64,405 | |
| 03-11-2022 | AH | 4:05 PM ET (Nov 3) |
ONCT | Oncternal Therapeutics, Inc. | 58.29 | -0.21 | -0.24 | -0.19 | Oncternal Therapeutics GAAP EPS of -$0.21 beats by $0.03, revenue of $0.38M beats by $0.13M [11/3/2022 4:15 PM] |
0.90 | -0.10 (-10.00%) |
1.03 | 0.03 (3.00%) |
0.69 - 4.49 | 464,971 | 150,000 | 671 | |
|
||||||||||||||||||
| 09-08-2022 | AH | 4:00 PM ET (Aug 9) |
ONCT | Oncternal Therapeutics | 57.00 | -0.23 | -0.23 | 0.00 | Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M [8/9/2022 4:12 PM] |
1.12 | 0.02 (1.35%) |
1.10 | -0.01 (-0.90%) |
0.69 - 4.63 | 695,874 | 510,000 | 35,424 | |
| 05-05-2022 | AH | 4:00 PM ET (May 5) |
ONCT | Oncternal Therapeutics, Inc. | 51.90 | -0.20 | -0.19 | -0.12 | Oncternal Therapeutics GAAP EPS of -$0.20 beats by $0.04, revenue of $0.7M beats by $0.17M [5/5/2022 4:38 PM] |
1.01 | -0.09 (-8.18%) |
1.04 | -0.06 (-5.45%) |
0.85 - 6.24 | 182,043 | 410,000 | 110 | |
| 10-03-2022 | AH | 4:05 PM ET (Mar 10) |
ONCT | Oncternal Therapeutics, Inc. | 77.60 | -0.16 | -0.25 | -0.09 | Oncternal Therapeutics reports Q4 results [3/10/2022 5:45 PM] |
1.55 | -0.13 (-7.74%) |
1.66 | -0.02 (-1.19%) |
1.52 - 10.56 | 502,192 | 210,000 | 101 | |
| 04-11-2021 | AH | 4:00 PM ET (Nov 4) |
ONCT | Oncternal Therapeutics, Inc. | 191.12 | -0.19 | -0.16 | -0.22 | Oncternal Therapeutics beats on revenue [11/4/2021 5:16 PM] |
4.19 | 0.12 (2.95%) |
4.15 | 0.08 (1.88%) |
1.64 - 10.56 | 1,033,963 | 420,000 | 2,200 | |
|
||||||||||||||||||
| 06-05-2021 | AH | 4:00 PM ET (May 6) |
ONCT | Oncternal Therapeutics, Inc. | 302.60 | -0.12 | -0.10 | -0.31 | Oncternal Therapeutics EPS misses by $0.02, misses on revenue [5/6/2021 4:31 PM] |
5.56 | 0.11 (2.02%) |
5.52 | 0.07 (1.28%) |
1.49 - 10.56 | 958,650 | 1,140,000 | 4,513 | |
| 11-03-2021 | AH | 5:15 PM ET (Mar 11) |
ONCT | Oncternal Therapeutics, Inc. | 263.34 | -0.09 | -0.18 | -0.27 | Oncternal Therapeutics EPS beats by $0.09, beats on revenue [3/11/2021 4:13 PM] |
7.50 | 1.13 (17.74%) |
6.88 | 0.51 (8.01%) |
1.49 - 8.65 | 3,031,415 | 1,378,490 | 40,420 | |
| 04-11-2020 | AH | 4:15 PM ET (Nov 4) |
ONCT | Gtx, Inc. | 31.00 | -0.22 | -0.30 | 0.00 | Oncternal Therapeutics reports Q3 results [11/4/2020 5:24 PM] |
3.29 | 1.78 (117.88%) |
1.63 | 0.12 (7.95%) |
1.49 - 6.29 | 85,577,773 | 51,350 | 590 | |
|
|
||||||||||||||||||
| 04-11-2020 | AH | 4:15 PM ET (Nov 4) |
ONCT | Oncternal Therapeutics, Inc. | 33.97 | -0.22 | -0.30 | -0.32 | Oncternal Therapeutics reports Q3 results [11/4/2020 5:24 PM] |
3.29 | 1.78 (117.88%) |
1.63 | 0.12 (7.95%) |
1.49 - 6.29 | 85,577,773 | 51,350 | 590 | |
|
|
||||||||||||||||||